Clofarabine

Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit[1].

Product Specifications

CAS Number

[123318-82-1]

UNSPSC

12352005

Hazard Statement

H300

Target

Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/clofarabine.html

Purity

99.88

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O[C@H]1[C@H](F)[C@H](N(C=N2)C3=C2C(N)=NC(Cl)=N3)O[C@@H]1CO

Molecular Formula

C10H11ClFN5O3

Molecular Weight

303.68

Precautions

H300

References & Citations

[1]Peter L Bonate, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006 Oct;5 (10) :855-63.|[2]Hai-Bo Liu, et al. [Effect of clofarabine on proliferation and Bcl-2 expression of NB4 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20 (3) :571-3.|[3]Jia-Jie Luan, et al. Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics. Kaohsiung J Med Sci. 2016 May;32 (5) :227-34.